Tirzepatide
Also sold as Mounjaro, Zepbound
Regulatory
Legal Status in 2026
FDA shortage resolved October 2, 2024; enforcement discretion for compounding has ended.
Federal law restricts compounding of this compound. For compounds whose FDA-declared shortage has resolved, Section 503B bulk compounding rights have ended; Section 503A compounding remains possible only with a documented patient-specific clinical justification (a verified allergy to an inactive ingredient, or a strength the manufacturer does not make, not cost or convenience). For compounds affirmatively excluded by the FDA's Pharmacy Compounding Advisory Committee, compounding is not permitted under the bulk-substance list. The FDA-approved product (where one exists) is the appropriate default.
Off the FDA drug shortage list. Verified June 1, 2026 via the openFDA drug shortage database.
FDA declared the shortage resolved on October 2, 2024. Enforcement discretion for compounding ended February 18, 2025 under Section 503A and March 19, 2025 under Section 503B. FDA announcement.
About
About Tirzepatide
A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.
Science
Mechanism of Action
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1R activation suppresses appetite, stimulates glucose-dependent insulin secretion, slows gastric emptying, and reduces glucagon. GIP receptor activation enhances insulin secretion synergistically, improves adipose tissue lipid metabolism, and may modulate central appetite regulation. The combination produces greater weight loss and metabolic improvement than GLP-1 agonism alone.
Dosing
Typical Protocol
Week 1–4: 2.5 mg subcutaneously once weekly. Week 5–8: 5 mg once weekly. Ongoing titration: increase by 2.5 mg every 4 weeks as tolerated, up to 15 mg/week. Maintenance: 10–15 mg once weekly for maximum efficacy. Contraindications mirror semaglutide: MEN2, medullary thyroid carcinoma, pancreatitis.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Supported by the clinical trial data required for FDA approval, representing the highest evidence bar. Safety and efficacy have been established in multiple phases of human clinical trials.
Providers advertising Tirzepatide
A tirzepatide mention is not a fulfillment check. FDA-approved tirzepatide is sold as Mounjaro and Zepbound. Before paying, ask which product is being dispensed and which pharmacy fills it.
Weight Watchers Med+Weight Loss Telehealth · Membership Model · LegitScript Certified
FuturHealthWeight Loss Telehealth · Specialty Focused · LegitScript Certified
Strive PharmacyCompounding Pharmacy · GLP-1 Specialist · PCAB Accredited
REMEVi HealthTelehealth Platform · LegitScript Certified
Ro (Roman Health)Men's Health Telehealth · GLP-1 Specialist · LegitScript Certified
Aspire HealthMen's Health Telehealth · GLP-1 Specialist
Elektra HealthWomen's Health Telehealth · Specialty Focused · LegitScript Certified
Form HealthWeight Loss Telehealth · Physicians Disclosed · LegitScript Certified
AgelessRxMen's Health Telehealth · GLP-1 Specialist
Get Thin MDMen's Health Telehealth · GLP-1 Specialist
Zeus Men's HealthTelehealth Platform · Physicians Disclosed
Big Easy Weight LossTelehealth Platform
Compound comparisons
Compare Tirzepatide
Tirzepatide set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.